BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20180621)

  • 1. Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
    Galons H; Oumata N; Meijer L
    Expert Opin Ther Pat; 2010 Mar; 20(3):377-404. PubMed ID: 20180621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New patented histone deacetylase inhibitors.
    Wang H; Dymock BW
    Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase inhibitors closer to market launch?
    Galons H; Oumata N; Gloulou O; Meijer L
    Expert Opin Ther Pat; 2013 Aug; 23(8):945-63. PubMed ID: 23600454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009.
    Poulsen SA
    Expert Opin Ther Pat; 2010 Jun; 20(6):795-806. PubMed ID: 20476848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule c-Met kinase inhibitors: a review of recent patents.
    Porter J
    Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pim kinase inhibitors: a survey of the patent literature.
    Morwick T
    Expert Opin Ther Pat; 2010 Feb; 20(2):193-212. PubMed ID: 20100002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review.
    Lavecchia A; Di Giovanni C; Novellino E
    Expert Opin Ther Pat; 2010 Mar; 20(3):405-25. PubMed ID: 20166845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinases as targets for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
    Dai Y
    Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.
    Magrioti V; Kokotos G
    Expert Opin Ther Pat; 2010 Jan; 20(1):1-18. PubMed ID: 20021282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments on JAK2 inhibitors: a patent review.
    Kiss R; Sayeski PP; Keserũ GM
    Expert Opin Ther Pat; 2010 Apr; 20(4):471-95. PubMed ID: 20205617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule pan-IAP antagonists: a patent review.
    Flygare JA; Fairbrother WJ
    Expert Opin Ther Pat; 2010 Feb; 20(2):251-67. PubMed ID: 20100005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors].
    Meijer L; Knockaert M; Damiens E
    Bull Cancer; 2001 Apr; 88(4):347-50. PubMed ID: 11371368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase inhibitors.
    Fischer PM; Endicott J; Meijer L
    Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.